Ac2-26, a mimetic peptide of full-length AnxA1 protein, shares the anti-inflammatory effects of glucocorticoids [28] and reduced cytokine storm syndrome especially in patients with severe COVID-19 illness, suggesting that it is a promising treatment for patients with severe respiratory symptoms and multiple organ involvement [29]. The gene discussed is ANXA1; the disease is COVID-19.